| Literature DB >> 29240409 |
Gabriele Cruciani1,2, Nicolò Milani1, Paolo Benedetti1,2, Susan Lepri1, Lucia Cesarini1, Massimo Baroni3, Francesca Spyrakis4, Sara Tortorella2,5, Edoardo Mosconi2,6, Laura Goracci1,2.
Abstract
Aldehyde oxidase (AOX) is a molibdo-flavoenzyme that has raised great interest in recent years, since its contribution in xenobiotic metabolism has not always been identified before clinical trials, with consequent negative effects on the fate of new potential drugs. The fundamental role of AOX in metabolizing xenobiotics is also due to the attempt of medicinal chemists to stabilize candidates toward cytochrome P450 activity, which increases the risk for new compounds to be susceptible to AOX nucleophile attack. Therefore, novel strategies to predict the potential liability of new entities toward the AOX enzyme are urgently needed to increase effectiveness, reduce costs, and prioritize experimental studies. In the present work, we present the most up-to-date computational method to predict liability toward human AOX (hAOX), for applications in drug design and pharmacokinetic optimization. The method was developed using a large data set of homogeneous experimental data, which is also disclosed as Supporting Information .Entities:
Mesh:
Substances:
Year: 2017 PMID: 29240409 DOI: 10.1021/acs.jmedchem.7b01552
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446